MPI Research strives to be the best CRO in preclinical and early clinical contract research.

Supporting all phases of drug development

See How

Need It, Want It, Gotta Do It: How to Optimize Your Nonclinical ADME Studies

Play Now

Reducing clinical failure early

Read How

We partner with Sponsors around the world to develop their drug and device programs. Every year, our experienced scientists and dedicated technical team conduct thousands of discovery, drug safety, bioanalytical, analytical, medical device, and clinical research studies.

We are committed to bring safer and more effective drugs and devices to the market faster and more efficiently.

With over 32,000 studies and counting and high satisfaction, MPI Research aims to be the CRO partner for your drug and device programs.

Submit Inquiry
IND-enabling Packages
Conducted Annually
People Dedicated to
Improving Healthcare
  • blog-reducing-clinical-failures

Reducing Clinical Failures through Early DMPK Studies

by Ric Slauter, PhD, DABT

Suppose a baseball team had a player whose batting average was a mere 0.0001. We can […]

  • blog-DMPK-partner

Finding the Right DMPK Partner

by Ric Slauter, PhD, DABT

The 20th century saw amazing, life-saving discoveries in medical research. That innovative spirit remains strong in […]

  • blog-strongest-rope-early-pk-pd-modeling

The Strongest Rope: Early PK-PD Modeling

by Ric Slauter, PhD, DABT

The strongest rope is one made of multiple cords woven tightly together. Likewise, applying the closely […]

“While MPI Research has been our ‘go-to’ nonclinical CRO for almost 10 years, they have become an extension of our in-house development team and their work on our most recent development candidate deserves particular praise. While many CROs advertise their ability to perform integrated nonclinical development packages to support first-in-human clinical studies, the MPI Research team has shown its ability to deliver on these promises. Their ability to meet our aggressive timelines for our latest development candidate is a product of the long-term relationship we have developed with the study team. This study team has worked with us over multiple development programs and therefore understands our products, needs and expectations, with the dedication to come together with a highly effective program management group. MPI Research has again shown their ability to initiate multiple studies rapidly, remain highly flexible when delays outside their control occur, and ultimately produce high quality studies. I look forward to our relationship with the MPI Research team over the coming years and to the warm welcome our company always receives when we visit Kalamazoo.”

Large Pharmaceutical Company

“I was very impressed with the MPI Research team’s care in animal handling and their established enrichment programs for our various carcinogenicity studies. I continue to share the excellence of their animal care programs with our partners and other CROs. I would like to thank all the team members involved in our studies for taking such great care of the animals.”

Executive Director,
Pharmaceutical Company

“We have developed an extremely productive partnership with MPI Research over the past several years. Through the many immunology, pharmacokinetic, and general toxicology studies we have conducted at MPI Research, we have received quality, on-time data that has allowed us to progress our compounds along the drug development pathway. We trust and appreciate the commitment to excellence and dedication of MPI Research and we look forward to expanding our partnership.”

Chief Study Director
Biotechnology Company

Let us take you further